5JA1 Stock Overview
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sprint Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.081 |
| 52 Week High | kr0.23 |
| 52 Week Low | kr0.02 |
| Beta | 0.61 |
| 1 Month Change | 16.57% |
| 3 Month Change | 9.92% |
| 1 Year Change | 184.86% |
| 3 Year Change | -83.77% |
| 5 Year Change | n/a |
| Change since IPO | -90.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5JA1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -15.6% | 0.8% | 1.2% |
| 1Y | 184.9% | -24.4% | 2.0% |
Return vs Industry: 5JA1 exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 5JA1 exceeded the German Market which returned 2% over the past year.
Price Volatility
| 5JA1 volatility | |
|---|---|
| 5JA1 Average Weekly Movement | 24.9% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5JA1's share price has been volatile over the past 3 months.
Volatility Over Time: 5JA1's weekly volatility has decreased from 52% to 25% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 28 | Johan Emilsson | www.sprintbioscience.com |
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes.
Sprint Bioscience AB (publ) Fundamentals Summary
| 5JA1 fundamental statistics | |
|---|---|
| Market cap | €7.70m |
| Earnings (TTM) | -€37.44k |
| Revenue (TTM) | €4.42m |
1.7x
P/S Ratio-205.6x
P/E RatioIs 5JA1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5JA1 income statement (TTM) | |
|---|---|
| Revenue | kr51.69m |
| Cost of Revenue | kr8.70m |
| Gross Profit | kr42.99m |
| Other Expenses | kr43.43m |
| Earnings | -kr438.00k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0063 |
| Gross Margin | 83.17% |
| Net Profit Margin | -0.85% |
| Debt/Equity Ratio | 0% |
How did 5JA1 perform over the long term?
See historical performance and comparison